Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Fluxergy, Mass General Brigham Partner to Evaluate Rapid COVID-19 Molecular Testing System

Fluxergy, Mass General Brigham Partner to Evaluate Rapid COVID-19 Molecular Testing System

Jun 30, 2020
|
staff reporter

NEW YORK – Fluxergy said on Monday that it is collaborating with Mass General Brigham (MGB, formerly Partners Healthcare) to evaluate Fluxergy's research-use-only COVID-19 molecular testing platform.

Fluxergy, based in Irvine, California, will specifically work with the MGB Center for COVID Innovation, said Fluxergy Chief Commercialization Officer Ali Tinazli.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Cost of Meeting Cancellations

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

Genetic Nondiscrimination Act Upheld

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

Enhancement Avoidance

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

PLOS Papers on Shigella Insertion Sequences, Antigens and Plasmodium vivax Diversity, More

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Infectious Disease

  1. Vela Diagnostics Automated Coronavirus Test Gets CE-IVD Mark

  2. FDA Grants EUA for UCSF, Broad Institute, BioSewoom Coronavirus Tests

  3. SARS-CoV-2 Pandemic May Promote Progress in Paper MDx

    Premium

  4. FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

  5. Paragon Genomics Betting Updated SARS-CoV-2 NGS Kit Will Enable High-Throughput Research, Testing

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.